Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 6/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.48 |
| ▸ | HTR3B | O95264 | 4/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5336736 | 0.85 | HTR3A (0.54) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL21246782 | 0.72 | HTR3A (0.56) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL21262258 | 0.71 | HTR3A (0.50) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL31078751 | 0.71 | HSD17B14 (0.49) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL20854390 | 0.71 | KDM4E (0.49) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL15651358 | 0.69 | PARP1 (0.50) | PARP1ALDH1A1CYP1A2THPOMAP4K4 | |
| SCHEMBL14558284 | 0.68 | MEN1 (0.48) | KDM4EALDH1A1CYP1A2RAB9A | |
| SCHEMBL5338538 | 0.68 | ALDH1A1 (0.54) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL7543196 | 0.68 | RAB9A (0.55) | KDM4EALDH1A1RAB9A | |
| SCHEMBL16742854 | 0.68 | HTR3A (0.47) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | BERGMANIS ARIJA A | 2005-11-17 | — | — | US | disclosed |
| US-6956052-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-18 | — | — | US | disclosed |
| EP-1501805-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1444207-A2 | SUBSTITUTED PYRAZOLYL-COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORARTION | 2004-06-10 | — | — | US | disclosed |
| WO-2003095430-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003024935-A2 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | HTR3A 2381/4885HTR3E 2713/4885HTR3B 2636/4885 |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | HTR3A 2381/4885HTR3E 2713/4885HTR3B 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.